Corrigendum: Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor

Front Pharmacol. 2023 Jun 2:14:1225522. doi: 10.3389/fphar.2023.1225522. eCollection 2023.

Laura Grohs^{1

2}, Linhan Cheng¹, Saskia Cönen^{1

3}, Bassam G Haddad³, Astrid Bülow^{1

4}, Idil Toklucu⁵, Lisa Ernst⁶, Jannis Körner^{5

7}, Günther Schmalzing¹, Angelika Lampert⁵, Jan-Philipp Machtens^{1

3}, Ralf Hausmann¹

¹ Institute of Clinical Pharmacology, RWTH Aachen University, Aachen, Germany.
² Department of Neurology, University Hospital, RWTH Aachen University, Aachen, Germany.
³ Molecular and Cellular Physiology (IBI-1), Institute of Biological Information Processing (IBI), Jülich, Germany.
⁴ Department of Plastic Surgery, Hand and Burn Surgery, University Hospital RWTH Aachen, Aachen, Germany.
⁵ Institute of Physiology (Neurophysiology), RWTH Aachen University, Aachen, Germany.
⁶ Institute for Laboratory Animal Science and Experimental Surgery, RWTH Aachen University, Aachen, Germany.
⁷ Department of Anesthesiology, University Hospital RWTH Aachen, Aachen, Germany.

Abstract

[This corrects the article DOI: 10.3389/fphar.2023.1120360.].

Keywords: P2X3 receptor; chronic pain; competitive antagonist; drug screening; nociception; non-steroidal anti-inflammatory drugs (NSAIDs).